ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2270

Changes in Cerebral Blood Flow Velocity in Patients with Familial Mediterranean Fever

Gozde Yildirim Cetin1, Uygar Utku2, Nurhan Atilla3, Kadir Gisi4 and Mehmet Sayarlioglu5, 1Deparment of Rheumatology, Sutcu Imam University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, Turkey, 2Neurology, Kahramanmaras Sutcu Imam University, Medical Faculty, Kahramanmaras, Turkey, 3Chest Diseases, Sutcu Imam University, School of Medicine, Kahramanmaras, Turkey, 4Gastroenterology, Sutcu Imam University, School of Medicine, Kahramanmaras, Turkey, 5Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Familial Mediterranean fever

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy and Miscellaneous Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose

Familial Mediterranean fever (FMF) is a hereditary and an auto-inflammatory disease predominantly characterized by repeated attacks of fever, abdominal pain, pleuritic chest pain, arthritis and erysipelas-like erythema.The MEditerranean FeVer (MEFV) gene mutations altering the structure and function of pyrin protein play a significant role in the pathophysiology of the disease. Mutated pyrin is associated with the loss of delicate control of the inflammatory pathways, which results in a prolonged or augmented inflammation that predisposes these patients to a pro-inflammatory state. This increased inflammation might lead to susceptibility to vascular comorbidities in FMF patients.  The aim of this study was to assess the effects of this increased inflammation on cerebral blood flow velocity with transcranial Doppler (TCD) ultrasonography.

Methods In this study, 30 subjects were enrolled for FMF and healthy control groups. All patients with FMF were under colchicine treatment and they were in an attack free period. Bilateral middle cerebral artery (MCA) peak-systolic, end-diastolic, and mean blood flow velocities; Gosling’s pulsatility index values; and Pourcelot’s resistance index values were recorded and compared with each other.  

Results

There were 30 subjects in each group. Men/women ratio and mean age in FMF and control groups were 4/3, 26/27 and 34,7±5,9 vs.32,3±4,7 respectively. Peak-systolic, end-diastolic, and mean blood flow velocities of bilateral MCA were  significantly higher in FMF group when compared with the control group (Table 1).  

Table 1 Transcranial Doppler data of FMF group compared with control group. 

 

FMF group

(mean±SD)

Control group

(mean±SD)

p-value

L-peak-systolic BFV

143,3± 19,5

104,5± 13

<0,001

L-end-diastolic BFV

56,4± 13,5

38,4± 6,2

<0,001

L-mean BFV

90,9± 13,8

61,8±  8,2

<0,001

L-PI

0,85  ± 0,07

0,9±0 ,09

0,02

L-RI

0,59± 0 ,03

0,6±0,05

0,57

R-peak-systolic BFV

145,2± 22,3

103,5± 17,05

<0,001

R-end-diastolic BFV

59,5±13

36,7± 12,36

<0,001

R-mean BFV

90,7±15,47

63,2± 10,5

<0,001

R-PI

0,8±0,08

0,85±0 ,09

0,89

R-RI

0,56± 0,04

0,63±0 ,06

0,002

L, left; R, right; PI, pulsatility index; RI, resistance index; BFV; blood flow velocity.

 Conclusion

There has been recently considerable attention concerning the possible causal role of systemic inflammation in the development of atherosclerosis in patients with rheumatic diseases. The attacks of FMF with clinical inflammation is only the tip of the iceberg, inflammation maintains in attack-free remission periods in 30% of patients with FMF. This maintaining subclinical inflammation induces endothelial dysfunction, and increases the risk of developing significant complications such as atherothrombosis, anemia, splenomegaly, decreased bone mineral density, heart disease, and life-threatening secondary systemic amyloidosis. In this study, we investigated the effects of clinical and subclinical inflammation regarding FMF disease on cerebral blood flow parameters. In our study, the mechanisms that underlie significantly increased blood flow velocities of  the FMF group is most likely to be due to mild diffuse subclinical atherosclerosis. Consequently, our results suggest that persistent clinical and subclinical inflammation in FMF patients  causes increased cerebral blood flow velocities.


Disclosure:

G. Yildirim Cetin,
None;

U. Utku,
None;

N. Atilla,
None;

K. Gisi,
None;

M. Sayarlioglu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-cerebral-blood-flow-velocity-in-patients-with-familial-mediterranean-fever/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology